DILACORT Gastro-resistant tablet Ref.[49968] Active ingredients: Prednisolone

Source: Health Products Regulatory Authority (IE)  Revision Year: 2021  Publisher: Crescent Pharma International Limited, 260 Trip San Albert, Gzira GZR 1150, Malta

4.3. Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
  • Systemic infections unless specific anti-infective therapy is employed.
  • Ocular herpes simplex because of possible perforation.

4.4. Special warnings and precautions for use

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (See Section 4.8). Symptoms typically emerge within a few days or weeks of starting the treatment. Risks may be higher with high doses systemic exposure (See also Section 4.5), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary. Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.

Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.

Tumorigenicity: direct tumour-inducing effects of the glucocorticoids are not known, but the particular risk that malignancies in patients undergoing immunosuppression with these or other drugs will spread more rapidly is a well-recognised problem (See Section 4.5).

Calciphylaxis may occur very rarely during treatment with corticosteroids (See Section 4.8). Although calciphylaxis is most commonly observed in patients who have end stage kidney failure, it has also been reported in patients taking corticosteroids who have minimal or no renal impairment and normal calcium, phosphate and parathyroid hormone levels. Patients/carers should be advised to seek medical advice if symptoms develop.

Caution is necessary when oral corticosteroids, including prednisolone, are prescribed in patients with the following conditions, and frequent patient monitoring is necessary.

  • Tuberculosis: Those with a previous history of, or X-ray changes characteristic of, tuberculosis. The emergence of active tuberculosis can, however, be prevented by the prophylactic use of anti-tuberculosis therapy.
  • Inflammatory bowel disease: Symptoms recurred in a patient with Crohn’s disease on changing from conventional to enteric-coated tablets of prednisolone. This was not an isolated occurrence in the author’s unit, and it was advocated that only non-enteric coated prednisolone tablets should be used in Crohn’s disease, and that the enteric coated form should be used with caution in any condition characterised by diarrhoea or a rapid transit time.
  • Hypertension.
  • Congestive heart failure.
  • Liver failure.
  • Hepatic disease: In patients with acute and active hepatitis, protein binding of the glucocorticoids will be reduced and peak concentrations of administered glucocorticoids increased. Elimination of prednisolone will also be impaired. There is an enhanced effect of corticosteroids in patients with cirrhosis.
  • Renal insufficiency.
  • Diabetes mellitus or in those with a family history of diabetes.
  • Osteoporosis: This is of special importance in post-menopausal females who are at particular risk.
  • Corticosteroid requirements may be reduced in menopausal and post-menopausal women.
  • Patients with a history of severe affective disorders and particularly those with a previous history of steroid-induced psychoses.
  • Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids including prednisolone.
  • Epilepsy, and/or seizure disorders
  • Peptic ulceration.
  • Previous steroid myopathy.
  • Glucocorticoids should be used cautiously in patients with myasthenia gravis receiving anticholinesterase therapy.
  • Because cortisone has been reported rarely to increase blood coagulability and to precipitate intravascular thrombosis, thromboembolism, and thrombophlebitis, corticosteroids should be used with caution in patients with thromboembolic disorders.
  • Duchenne’s muscular dystrophy: transient rhabdomyolysis and myoglobinuria may occur following strenuous physical activity. It is not known whether this is due to prednisolone itself or the increased physical activity. Undesirable effects may be minimised by using the lowest effective dose for the minimum period and by administering the daily requirement as a single morning dose on alternate days. Frequent patient review is required to titrate the dose appropriately against disease activity (See Section 4.2).

Adrenocortical Insufficiency

Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of glucocorticoid therapy.

In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly. Drug-induced secondary adrenocortical insufficiency may therefore be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. During prolonged therapy any intercurrent illness, trauma, or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced.

Patients should carry “Steroid treatment” cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of prescriber, drug, dosage and the duration of treatment.

Anti-inflammatory/Immunosuppressive effects and Infection

Suppression of the inflammatory response and immune function increases the susceptibility to infections and their severity. The clinical presentation may often be atypical and serious infection such as septicaemia and tuberculosis may be masked and may reach an advanced stage before being recognised when corticosteroids including prednisolone are used. The immunosuppressive effects of glucocorticoids may result in activation of latent infection or exacerbation of intercurrent infections.

Chickenpox

Chickenpox is of particular concern since this normally minor illness may be fatal in immunosuppressed patients. Patients (or parents of children) without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention. Passive immunisation with varicella-zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are receiving systemic corticosteroids or who have used them within the previous 3 months; this should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is confirmed, the illness warrants specialist care and urgent treatment. Corticosteroids should not be stopped and the dose may need to be increased.

Measles

Patients should be advised to take particular care to avoid exposure to measles, and to seek immediate medical advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin may be needed.

Administration of Live Vaccines

Live vaccines should not be given to individuals on high doses of corticosteroids, due to impaired immune response. Live vaccines should be postponed until at least 3 months after stopping corticosteroid therapy. (See also section 4.5).

Ocular Effects

Prolonged use of corticosteroids may produce posterior subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves. Establishment of secondary fungal and viral infections of the eye may also be enhanced in patients receiving glucocorticoids.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible perforation.

Systemic glucocorticoid treatment can cause severe exacerbation of bullous exudative retinal detachment and lasting visual loss in some patients with idiopathic central serous chorioretinopathy (See Section 4.8).

Cushing’s disease

Because glucocorticoids can produce or aggravate Cushing’s syndrome, glucocorticoids should be avoided in patients with Cushing’s disease

There is an enhanced effect of corticosteroids in patients with hypothyroidism.

Psychic derangements may appear when corticosteroids, including prednisolone, are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations (See Section 4.8).

Raised intracranial pressure

Raised intracranial pressure with papilloedema (pseudotumour cerebri) associated with corticosteroid treatment has been reported in both children and adults. The onset usually occurs after treatment withdrawal (See Section 4.8).

Scleroderma renal crisis

Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more prednisolone. Blood pressure and renal function (s-creatinine) should therefore be routinely checked. When renal crisis is suspected, blood pressure should be carefully controlled.

Elderly

Treatment of elderly patients, particularly if long term, should be planned bearing in mind the more serious consequences of the common side-effects of corticosteroids in old age, especially osteoporosis, diabetes, hypertension, hypokalaemia, susceptibility to infection and thinning of the skin. Close clinical supervision is required to avoid life threatening reactions.

Paediatric population

Corticosteroids cause growth retardation in infancy, childhood and adolescence, which may be irreversible, and therefore long-term administration of pharmacological doses should be avoided. If prolonged therapy is necessary, treatment should be limited to the minimum suppression of the hypothalamo-pituitary adrenal axis and growth retardation. The growth and development of infants and children should be closely monitored. Treatment should be administered where possible as a single dose on alternate days.

There is an increased risk of nuclear cataracts (See Section 4.8).

Excipients

This medicine contains 69,50mg of lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5. Interaction with other medicinal products and other forms of interaction

Vaccines Live vaccines should not be given to individuals with impaired immune
responsiveness. The antibody response to other vaccines may be diminished.
Antacids The absorption of prednisolone may be reduced by large doses of some antacids
such as magnesium trisilicate or aluminium hydroxide.
AntibacterialsRifamycins accelerate metabolism of corticosteroids and thus may reduce their
effect. Erythromycin inhibits metabolism of methylprednisolone and possibly other
corticosteroids.

Prednisolone can lower plasma levels of isoniazid. Where a reduced response
during concurrent use is noted, dosage adjustment of isoniazid may be necessary.
AnticoagulantsResponse to anticoagulants may be reduced or, less often, enhanced by
corticosteroids. Close monitoring of the INR or prothrombin time is required to
avoid spontaneous bleeding.
Antidiabetic agentsGlucocorticoids may increase blood glucose levels. Patients with diabetes mellitus
receiving concurrent insulin and/or oral hypoglycemic agents may require dosage
adjustments of such therapy.
AntiepilepticsCarbamazepine, phenobarbital, phenytoin, and primidone accelerate metabolism of
corticosteroids and may reduce their effect.
AntifungalsRisk of hypokalaemia may be increased with amphotericin, therefore concomitant
use with corticosteroids should be avoided unless corticosteroids are required to
control reactions; ketoconazole inhibits metabolism of methylprednisolone and
possibly other corticosteroids.
Antimuscarinics
(Anticholinergics)
Prednisolone has been shown to have antimuscarinic activity. If used in combination
with another antimuscarinic drug could cause impairment to memory and attention
in the elderly.
Antithyroids Prednisolone clearance increased by the use of carbimazole and thiamazole.
Cardiac Glycosides Increased toxicity if hypokalaemia occurs with corticosteroids.
CiclosporinConcomitant administration of prednisolone and ciclosporin may result in
decreased plasma clearance of prednisolone (i.e. increased plasma concentration of
prednisolone). The need for appropriate dosage adjustment should be considered
when these drugs are administered concomitantly.
Cytotoxics Increased risk of haematological toxicity with methotrexate.
Hepatic microsomal
enzyme inducers
Drugs that induce hepatic enzyme cytochrome P-450 (CYP) isoenzyme 3A4 such as
phenobarbital, phenytoin, rifampicin, rifabutin, carbamazepine, primidone and
aminoglutethimide may reduce the therapeutic efficacy of corticosteroids by
increasing the rate of metabolism. Lack of expected response may be observed and
dosage of Dilacort Gastro-resistant tablets may need to be increased.
Hepatic microsomal enzyme inhibitorsDrugs that inhibit hepatic enzyme cytochrome P-450 (CYP) isoenzyme 3A4 (e.g.
ketoconazole, troleandomycin) may decrease glucocorticoid clearance. Dosages of
glucocorticoids given in combination with such drugs may need to be decreased to
avoid potential adverse effects.
Hormonal contraceptivesOral contraceptives increased prednisolone concentrations by 131%.
May increase AUC and reduce clearance in oral contraceptives containing
ethinylestradiol, mestranol, desogestrel, levonorgestrel, norgestrel or norethisterone.
ImmunosuppressantsTumorigenicity: direct tumour-inducing effects of the glucocorticoids are not known,
but the particular risk that malignancies in patients undergoing immunosuppression
with these or other drugs will spread more rapidly is a well- recognised problem.
Liquorice Glycyrrhizin can delay the clearance of prednisolone.
Mifepristone Effect of corticosteroids may be reduced for 3-4 days after mifepristone.

4.6. Pregnancy and lactation

Pregnancy

The ability of corticosteroids to cross the placenta varies between individual drugs, however 88% of prednisolone is inactivated as it crosses the placenta. Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-uterine growth retardation and effects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate/lip in man. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to corticosteroids but usually resolves spontaneously following birth and is rarely clinically important. Cataracts have been observed in infants born to mothers treated with long-term prednisolone during pregnancy. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. When corticosteroids are essential however, patients with normal pregnancies may be treated as though they were in the non-gravid state.

Patients with pre-eclampsia or fluid retention require close monitoring.

Breast-feeding

Corticosteroids are excreted in small amounts in breast milk. Corticosteroids distributed into breast milk may suppress growth and interfere with endogenous glucocorticoid production in nursing infants. Since adequate reproductive studies have not been performed in humans with glucocorticoids, these drugs should be administered to nursing mothers only if the benefits of therapy are judged to outweigh the potential risks to the infant.

The concentration of the steroid in the milk can be between 5 and 25% of those in the serum and the two roughly parallel one another after an oral dose.

There are no reports found regarding neonatal toxicity following exposure to corticosteroids during breast-feeding, however if maternal doses >40mg/day of prednisolone is prescribed, the infant should be monitored for adrenal suppression.

4.7. Effects on ability to drive and use machines

The effect of Dilacort gastro-resistant tablets on the ability to drive or use machinery has not been evaluated. There is no evidence to suggest that prednisolone may affect these abilities.

4.8. Undesirable effects

A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported. Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown.

The incidence of predictable undesirable effects, including hypothalamic-pituitary adrenal suppression correlates with the relative potency of the drug, dosage, timing of administration and the duration of treatment (See Section 4.4).

Undesirable effects are listed by MedDRA System Organ Classes.

Assessment of undesirable effects is based on the following frequency groupings: Very common: ≥1/10, Common: ≥1/100 to <1/10, Uncommon: ≥1/1,000 to <1/100, Rare: ≥1/10,000 to <1/1,000, Very rare: <1/10,000, Not known: cannot be estimated from the available data.

System Organ ClassFrequencyUndesirable Effect
Infections and infestations Not knownIncreases susceptibility to, and severity of infections1,
opportunistic infections, recurrence of dormant
tuberculosis2, oesophageal candidiasis.
Blood and lymphatic system disorders Not known Leucocytosis.
Immune system disorders Not knownHypersensitivity including anaphylaxis.
Scleroderma renal crisis3
Endocrine disorders Not knownSuppression of the hypothalamo-pituitary adrenal axis4,
cushingoid facies, impaired carbohydrate tolerance with
increased requirement for antidiabetic therapy,
manifestation of latent diabetes mellitus.
Metabolism and nutrition disorders Not knownSodium and water retention, hypokalaemic alkalosis,
potassium loss, negative nitrogen and calcium balance,
glucose intolerance and protein catabolism. Increase both
high and low density lipoprotein cholesterol concentration
in the blood. Increased appetite5. Weight gain, obesity,
hyperglycaemia, dyslipidaemia.
Very rare Calciphylaxis6.
Psychiatric disorders CommonIrritability, depressed and labile mood, suicidal thoughts,
psychotic reactions, mania, delusions, hallucinations, and
aggravation of schizophrenia, behavioural disturbances,
irritability, anxiety, sleep disturbances, and cognitive
dysfunction including confusion and amnesia.
Not known Euphoria, psychological dependence, depression.
Nervous system disorders Not knownDepression, insomnia, dizziness, headache, vertigo. Raised
intracranial pressure with papilloedema (pseudotumor
cerebri)7. Aggravation of epilepsy, epidural lipomatosis,
vertebrobasilar stroke8.
Eye disorders Not knownGlaucoma, papilloedema, posterior subcapsular cataracts,
nuclear cataracts (particularly in children), exophthalmos,
corneal or scleral thinning, exacerbation of ophthalmic
viral or fungal disease.

Severe exacerbation of bullous exudative retinal
detachment; lasting visual loss in some patients with
idiopathic central serous chorioretinopathy9.
Ear and labyrinth disorders Not known Vertigo.
Cardiac disorders Not knownCongestive heart failure in susceptible patients,
hypertension, increased risk of heart failure. Increased risk
of cardiovascular disease, including myocardial infarction10.
Bradycardia*
Vascular disorders Not known Thromboembolism.
Gastrointestinal disorders Not knownDyspepsia, nausea, peptic ulceration with perforation and
haemorrhage, abdominal distension, abdominal pain,
diarrhoea, oesophageal ulceration, acute pancreatitis.
Skin and subcutaneous tissue disorders Not known Hirsutism, skin atrophy, bruising, striae, telangiectasia,
acne, increased sweating, pruritis, rash, urticaria.
Musculoskeletal and connective tissue disorders Not knownProximal myopathy, osteoporosis, vertebral and long bone
fractures, avascular osteonecrosis, tendon rupture,
tendinopathies (particularly of the Achilles and patellar
tendons), myalgia, growth suppression in infancy,
childhood and adolescence.
Reproductive system and breast disorders Not known Menstrual irregularity, amenorrhoea.
General disorders and administration site conditions Not known Fatigue, malaise, impaired healing.
Investigations Not knownIncreased intra-ocular pressure, may suppress reactions to
skin tests.

1 With suppression of clinical symptoms and signs.
2 See Section 4.4 Special warnings and precautions for use.
3 Amongst the different subpopulations the occurrence of scleroderma renal crisis varies. The highest risk has been
reported in patients with diffuse systemic sclerosis. The lowest risk has been reported in patients with limited
systemic sclerosis (2%) and juvenile onset systemic sclerosis (1%).
4 Particularly in times of stress, as in trauma, surgery or illness.
5 Which may result in weight gain.
6 See section 4.4 Special warnings and precautions for use.
7 Usually after treatment withdrawal.
8 Exacerbation of giant cell arteritis, with clinical signs of evolving stroke has been attributed to prednisolone.
9 See section 4.4 Special warnings and precautions for use.
10 With high dose therapy.
* Following high doses

Withdrawal symptoms

Too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death (See Sections 4.4 and 4.2). A steroid “withdrawal syndrome” seemingly unrelated to adrenocortical insufficiency may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules, weight loss, and/or hypotension. Theseeffects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels. Psychological effects have been reported on withdrawal of corticosteroids.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Website: www.hpra.ie.

6.2. Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.